|
Study Title |
Indication |
Clinical
Trial
Number |
Principal
Investigator |
Contact |
|
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer |
Breast Cancer |
B-39 |
C. Kesslering, MD |
Claudia Fredian, RN 630-352-5361 |
|
A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer |
Breast Cancer |
R 1005 |
C. Kesslering, MD |
Claudia Fredian, RN 630-352-5361 |
|
A Randomized Phase III Trial of Adjuvant Therapy ComparingChemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer |
Breast Cancer |
B-47 |
J. Ayers, MD (CDH) P. Menini, DO (Delnor)
|
Claudia Fredian, RN 630-352-5361 |
|
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER-2-Positive Ductal Carcinoma In Situ Resected by Lympectomy |
Breast Cancer |
B-43 |
J. Ayers, MD (CDH) P. Menini, DO (Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
A Randomized Double Blinded Phase III Study Comparing Gemcitabine, Cisplatin , and Bevacizumab (IND#7921) to Gemcitabine, Cisplatin and Placebo in Patients with Advanced Transitional Cell Carcinoma |
Bladder Cancer |
C 90601 |
M. Kahn, MD (CDH)
C. George, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
A Prospective Observational Multicenter Cohort Study To Assess The Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastasis Starting Zoledronic Acid Treatment |
Bone Metastasis |
S702 |
J. Ayers, MD (CDH) P. Menini, DO (Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial |
Cervical Cancer |
G0274 |
B. Buttin, MD |
Claudia Fredian, RN 630-352-5361 |
|
A Randomized, Double-Blind, Multicenter, Phase III study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients with metastatic Colorectal Carcinoma Progressive During or Following First-Line combination therapy |
Colorectal Cancer |
I4T-MC-JVBB |
M. Kahn, MD
(CDH)
A.Ragam, MD (Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
A Phase III Trial of Pelvic Radiation Therapy vs. Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin in Patients with High-Risk, Early Stage Endometrial Cancer |
Endometrial Cancer |
G0249 |
B. Buttin, MD |
Claudia Fredian, RN 630-352-5361 |
|
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin & Paclitaxel vs. Carboplatin & Paclitaxel for Optimally Debulked Advanced Endometrial Carcinoma |
Endometrial Cancer |
G0258 |
B. Buttin, MD |
Claudia Fredian, RN 630-352-5361 |
|
A Phase II Study of MK-2206 (NSC-749607) as Second Line Therapy for Advanced Gastric and Gastroesophageal Junction Cancer |
Gastro Esophageal
Cancer |
S1005
|
M. Kahn, MD
(CDH)
A.Ragam, MD (Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
A Genetic Risk-Stratified, Randomized Phase II Study of Four Fludarabine/Antibody Combinations for Patients with Symptomatic Previously Untreated Chronic Lymphocytic Leukemia |
Chronic Lymphocytic Leukemia (CLL) |
C10404 |
J. Ayers, MD
(CDH)
R. Bayer, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
Studying Interventions for Managing Patients with Chronic Myeloid Leukemia in Chronic Phase: The 5 Year Prospective CohortStudy |
Chronic Myeloid Leukemia (CML) |
SIMPLICITY |
J. Ayers, MD
(CDH)
R. Bayer, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
A Randomized Controlled Study of Yondelis (trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated with and Anthracycline and Ifosfamide |
Liposarcoma or Leiomyo-sarcoma |
ET743-SAR-3007 |
J. Ayers, MD |
Claudia Fredian, RN 630-352-5361 |
|
A Phase III Evaluation of Docetaxel and Gemcitabine Plus G-CSF with Bevacizumab Versus Docetaxel and Gemcitabine Plus G-CSF with Placebo in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus |
Uterine Leiomyosarcoma |
G250 |
B. Buttin, MD |
Claudia Fredian, RN 630-352-5361 |
|
A Phase III Randomized, Double Blind Trial of Chemoembolization with or without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients with and without Vascular Invasion |
Liver Cancer |
E1208 |
M. Kahn, MD
(CDH)
C. George, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage 1B-IIIA Non-Small Cell Lung Cancer |
Lung Cancer, Non-Small Cell |
E1505 |
L. Ferris, MD
(CDH)
P. Menini, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
A Randomized phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer |
Lung Cancer, Non-Small Cell |
S0819 |
L. Ferris, MD
(CDH)
P. Menini, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC |
Lung Cancer, Non-Small Cell |
E5508 |
L. Ferris, MD
(CDH)
P. Menini, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkins Lymphoma using Early Interim FDG-PET Imaging |
Hodgkin’s Lymphoma |
S0816 |
J. Ayers, MD
(CDH)
R. Bayer, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
A Phase I/II Trial of Vorinostat (SAHA) (NSC-701852) in Combination With Rituximab-CHOP in Patients With Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) |
B-Cell Lymphoma |
S806 |
J. Ayers, MD
(CDH)
R. Bayer, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
Randomized phase III trial comparing the frequency of major erythroid response (MER) to treatment with Lenalidomide (Revlimid) alone and in combination with Epoetin Alfa (Procrit) in subjects with Low-or Intermediate-1 risk MDS and Symptomatic Anemia |
Myleodysplastic syndrome (MDS) |
E2905 |
J. Ayers, MD
(CDH)
R. Bayer, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
A Prospective, Longitudinal Study (Phase II) of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy |
Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
G235 |
B. Buttin, MD |
Claudia Fredian, RN 630-352-5361 |
|
Randomized Phase III Trial of maintenance chemo comparing 12 monthly cycles of single agent Paclitaxel or CT-2103 versus no treatment until documented relapse in women with advanced ovarian primary peritoneal or fallopian tube cancer who achieve a complete clinical response to primary platinum/taxane based chemotherapy |
Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
G212 |
B. Buttin, MD |
Claudia Fredian, RN 630-352-5361 |
|
Chemotherapy Toxicity In Elderly Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
Ovarian, Primary Peritoneal or Fallopian Tube Cancer |
G273 |
B. Buttin, MD |
Claudia Fredian, RN 630-352-5361 |
|
Randomized Phase III Study of Neoajuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High Risk, Clinically localized Prostate Cancer |
Prostate Cancer |
C90203 |
M. Kahn, MD
(CDH)
C. George, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study |
Renal Cancer (Kidney Cancer) |
S0931 |
M. Kahn, MD
(CDH)
C. George, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |
|
Pathologic review for any Hematological malignancies diagnosed at any time |
Leukemias, Lymphomas |
CASE 5Z08 |
J. Ayers, MD
(CDH)
R. Bayer, MD
(Delnor) |
Claudia Fredian, RN 630-352-5361 |